Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to continue the Cooperative Centers on Human Immunology (CCHI) program to support studies that will advance understanding of the mechanisms regulating human immune responses. The immediate objective of CCHI is to support mechanistic and hypothesis-testing studies to understand human immunity applicable to the biodefense effort; i.e. innate, adaptive and mucosal immune responses to infection, vaccination and adjuvants. Studies on immune-mediated diseases (e.g. airway allergy, food allergy, autoimmunity, organ transplant rejection) are also of interest, as these data will provide a more comprehensive understanding of the human immune system. The program will also support the centralized infrastructure needed to promote and coordinate multi-disciplinary research in human immunology. Additional objectives are to promote public access to CCHI-supported data and metadata through public portals such as ImmPort, and to develop new technologies to support human immunology research.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

The goal of this Funding Opportunity Announcement (FOA) is to improve understanding of how durable protective immunity is achieved by supporting studies that define components and mechanisms of the immune system. Applications proposing human cells/tissue response studies will help determine the human responses elicited by immunization, however, animal studies may also be used to extend the findings from human tissues to more mechanistic studies not easily accomplished in humans.

This Funding Opportunity Announcement (FOA) solicits renewal applications for Biobanks that will support the following NCI clinical trial programs: The NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/), and NCI Community Oncology Research Program (NCORP). The NCTN Biospecimen Bank (also referred to as NCTN Biobanks) will be responsible for collecting, processing, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded NCTN Phase II-III and other clinical treatment trials (CTEP/Division of Cancer Treatment and Diagnosis; DCTD). The main goal is to support NCTN with the state-of the-art banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Biobanks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Biobanks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers as well as affiliated institutions to ensure effective operation. Each Biobank needs to maintain association with one specific NCTN Group and needs to be endorsed in that role by the group leaders. NCTN Biobanks will also support biobanking and storage of biospecimens from NCORP cancer control and prevention trials (NCORP/Division of Cancer Prevention; DCP).

The main goal of this limited competition Funding Opportunity Announcement (FOA) is to continue the state-of the-art biobanking infrastructure and operations for early-stage and experimental clinical trials sponsored by the National Cancer Institute (NCI). The biobanking needs of the following NCI clinical trial programs will be supported: Experimental Therapeutics Clinical Trials Network (ETCTN), and Other NCI-supported early and experimental trials. Currently, this biobanking infrastructure supporting NCI early experimental clinical trials is part of a biobank serving primarily another NCI program, National Clinical Trials Network (NCTN). Through a separate U24 award under this FOA, the NCI aims to separate the existing ETCTN-serving biobanking infrastructure and operation from the current NCTN Biobank. This separated entity will be termed: Early-Phase and Experimental Clinical Trials Biospecimen Bank (also referred to as EET Biobank). Although the EET Biobank and the "parent" NCTN Biobank may be hosted in the same institution, they are expected to become independent operations with separate leaderships. EET Biobank will be responsible for collecting, processing, storing a variety of human specimens from patients with cancer who are participating in NCI-funded ETCTN and other NCI-supported early and experimental clinical trials. The responsibilities of EET Bank will also include maintenance of up-to-date specimen inventory and specimen distribution to qualified NCI-approved trial investigators and research laboratories.

The Rheumatology Research Foundation is issuing a notice of special interest (NOSI) to highlight the availability of funds for projects exploring the relationships between rheumatic and musculoskeletal diseases and SARS-CoV-2, the virus that causes COVID-19. The Foundation accepts submissions within the following scientific categories: * Basic Science * Translational Science * Clinical Science * Health Services Research * Patient- or Practice-Centered Research Examples of studies relevant to this NOSI include, but are not limited to: * Immune responses to SARS-CoV-2 and pathogenesis of COVID-19 in patients with RMDs * Influence of DMARDs, biologic agents, or other medications, on SARS-CoV-2 immune responses * Studies of DMARDs or biologic agents used in RMDs on outcomes of SARS-CoV2 infection in animal models or in vitro * Epidemiology, clinical characteristics, and outcomes of CoVID-19 course in patients with RMDs, including the influence of therapeutic agents or other interventions in pragmatic trials * The effects of COVID-19 on access to rheumatology care, including telehealth, digital tools, social determinants of health, etc. * Analyses of the economic impact of COVID-19 on the care of patients with RMDs

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs.  The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs.  The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.   

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers.  Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery.  Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources.  Use of existing technologies to develop new reagents or genetic lines of significant value to the research community may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable.

This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers.  Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery.  Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources.  Use of existing technologies to develop new reagents or genetic lines of significant value to the research community may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable.

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

The study of gambling disorder remains an emerging field. In order to advance understanding of this disorder, the National Center for Responsible Gaming (NCRG) created the NCRG Center of Excellence in Gambling Research grants program in 2009. The first recipients of center grants-the University of Minnesota, The University of Chicago and Yale University-have made exceptional strides in advancing research on disordered gambling behavior. The NCRG is pleased to continue this program in 2016 by inviting proposals for the third round of grants in support of Centers of Excellence in Gambling Research in 2016.

The study of gambling disorder remains an emerging field. In order to advance understanding of this disorder, the National Center for Responsible Gaming (NCRG) created the NCRG Center of Excellence in Gambling Research grants program in 2009. The first recipients of center grants-the University of Minnesota, The University of Chicago and Yale University-have made exceptional strides in advancing research on disordered gambling behavior. The NCRG is pleased to continue this program in 2016 by inviting proposals for the third round of grants in support of Centers of Excellence in Gambling Research in 2016.

The purpose of this funding opportunity announcement (FOA) is to support innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

The purpose of this funding opportunity announcement (FOA) is to support innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

The focus of this Funding Opportunity Announcement (FOA) is to better understand how existing non-invasive neuromodulation devices affect brain circuity. This information should shed light on dose/response relationships that could be used for neuroscience applications and clinical interventions.

This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging software tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative software tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those software tools in prospective multisite clinical trials to test software tool performance and to demonstrate that the software tool can be integrated into clinical workflow with a minimum of disruption.

The purpose of this cooperative agreement is: To conduct and monitor epidemiologic, clinical, and laboratory-based projects, surveillance, and research of important diseases in Liberia. To incorporate the results of research activities into operational disease detection, prevention, and response or control programs in Liberia and ensure the strengthening of local workforce capacity and dissemination of findings across the region, with partners, and globally.

To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on developing courses for skills development - specifically, exportable training modules designed to enhance the rigor, reproducibility, and responsible conduct of biomedical data science research, targeted to trainees and researchers at any career level.

This notice solicits applications for the Resilient and Responsive Health Systems (RRHS) Initiative - South Sudan, a multi-year program to strengthen human resources for health (HRH) to address public health challenges like HIV/AIDS, tuberculosis (TB) and malaria in South Sudan. This initiative also seeks to achieve health system resiliency by addressing fundamental health systems constraints that impede the availability of and access to quality health services by supporting the implementation of national health strategies and recovery plans to respond to emerging epidemics, prevent, manage and control HIV/AIDS, TB, malaria, and other communicable and non-communicable diseases, and improve population health outcomes.

The BioWatch Program is a cornerstone of the Department of Homeland Security's (DHS) comprehensive strategy for countering biological terrorism. The BioWatch Program is an early warning system that is designed to detect the intentional release of select aerosolized biological agents. The BioWatch Program's mission is to provide and maintain a continuous bio-terrorism air monitoring system in metropolitan areas and coordinate with state and local public health communities to prepare for and respond to a bioterrorist event. This mission is accomplished by serving as an early warning system which enhances the security of jurisdictions by providing the needed time to execute their comprehensive concept of operations plans to counter biological terrorism. The Biowatch Program is a critical part of an ongoing national effort to build and sustain preparedness which helps the United States to maintain momentum through targeted jurisdictional planning that highlights preventative actions necessary to allow for a proper and timely response and begin the process to recovery from a biological agent release.

This Developmental Research Funding Opportunity intends to support gene function studies in collaboration with the Undiagnosed Diseases Network (UDN) building upon the NIH Intramural Research Programs Undiagnosed Diseases Program (NIH-UDP). Responsive applications will propose to investigate the underlying genetics, biochemistry and/or pathophysiology of newly diagnosed diseases in association with the respective gene variant(s) identified through the UDN. In recent years, gene function studies combined with genetic and genomic analyses and metabolic studies have greatly improved diagnoses of these very rare diseases and advanced scientific knowledge of the underlying pathogenesis. This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.